| http://purl.uniprot.org/citations/19043454 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/19043454 | http://www.w3.org/2000/01/rdf-schema#comment | "A defining feature of basal-like breast cancer, a breast cancer subtype with poor clinical prognosis, is the high expression of 'proliferation signature' genes. We identified B-Myb, a MYB family transcription factor that is often amplified and overexpressed in many tumor types, as being highly expressed in the proliferation signature. However, the roles of B-Myb in disease progression, and its mammary-specific transcriptional targets, are poorly understood. Here, we showed that B-Myb expression is a significant predictor of survival and pathological complete response to neoadjuvant chemotherapy in breast cancer patients. We also identified a significant association between the G/G genotype of a nonsynonymous B-Myb germline variant (rs2070235, S427G) and an increased risk of basal-like breast cancer [OR 2.0, 95% CI (1.1-3.8)]. In immortalized, human mammary epithelial cell lines, but not in basal-like tumor lines, cells ectopically expressing wild-type B-Myb or the S427G variant showed increased sensitivity to two DNA topoisomerase IIalpha inhibitors, but not to other chemotherapeutics. In addition, microarray analyses identified many G2/M genes as being induced in B-Myb overexpressing cells. These results confirm that B-Myb is involved in cell cycle control, and that its dysregulation may contribute to increased sensitivity to a specific class of chemotherapeutic agents. These data provide insight into the influence of B-Myb in human breast cancer, which is of potential clinical importance for determining disease risk and for guiding treatment."xsd:string |
| http://purl.uniprot.org/citations/19043454 | http://purl.org/dc/terms/identifier | "doi:10.1038/onc.2008.430"xsd:string |
| http://purl.uniprot.org/citations/19043454 | http://purl.uniprot.org/core/author | "Parker J.S."xsd:string |
| http://purl.uniprot.org/citations/19043454 | http://purl.uniprot.org/core/author | "Perou C.M."xsd:string |
| http://purl.uniprot.org/citations/19043454 | http://purl.uniprot.org/core/author | "Thorner A.R."xsd:string |
| http://purl.uniprot.org/citations/19043454 | http://purl.uniprot.org/core/author | "Hoadley K.A."xsd:string |
| http://purl.uniprot.org/citations/19043454 | http://purl.uniprot.org/core/author | "Millikan R.C."xsd:string |
| http://purl.uniprot.org/citations/19043454 | http://purl.uniprot.org/core/author | "Winkel S."xsd:string |
| http://purl.uniprot.org/citations/19043454 | http://purl.uniprot.org/core/date | "2009"xsd:gYear |
| http://purl.uniprot.org/citations/19043454 | http://purl.uniprot.org/core/name | "Oncogene"xsd:string |
| http://purl.uniprot.org/citations/19043454 | http://purl.uniprot.org/core/pages | "742-751"xsd:string |
| http://purl.uniprot.org/citations/19043454 | http://purl.uniprot.org/core/title | "In vitro and in vivo analysis of B-Myb in basal-like breast cancer."xsd:string |
| http://purl.uniprot.org/citations/19043454 | http://purl.uniprot.org/core/volume | "28"xsd:string |
| http://purl.uniprot.org/citations/19043454 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/19043454 |
| http://purl.uniprot.org/citations/19043454 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/19043454 |
| http://purl.uniprot.org/uniprot/#_P10244-mappedCitation-19043454 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/19043454 |
| http://purl.uniprot.org/uniprot/P10244 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/19043454 |